COMMENT|ONLINE FIRST Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants Carlos K H Wong, Kristy T K Lau, Gabriel M Leung Lancet Infect Dis Published: February 10, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00056-7 Over the past year of the COVID-19 pandemic, populations worldwide have been facing the constant threat of the SARS-CoV-2 omicron variant and its sublineages, and the high transmissibility and ...

ARTICLES|ONLINE FIRST Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022 Nana Wu, Keven Joyal-Desmarais, Paula A B Ribeiro, et al. Lancet Respir Med Published: February 10, 2023 DOI:https://doi.org/10.1016/S2213-2600(23)00015-2 Summary Background Synthesising evidence on the long-term vaccine effect...

Shifting Sepsis Quality Measures From Processes to Outcomes Sepsis is a significant health issue that leads to high rates of death and disability, with over 250,000 adult deaths annually in the U.S. alone. Healthcare providers, patients, regulatory agencies, and advocates for quality improvement acknowledge the importance of preventing sepsis and improving its outcomes.  The Severe Sepsis/Septic Shock Early Management Bundle (SEP-1) from the Centers for Med...

ARTICLES|ONLINE FIRST Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials Alain Amstutz, Benjamin Speich, France Mentré, et al. Lancet Respir Med Published:February 21, 2023 DOI:https://doi.org/10.1016/S2213-2600(22)00528-8 Summary Background Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in...

ARTICLES|ONLINE FIRST Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials Zhi-Rong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al. Lancet Microbe Published: February 28, 2023 DOI:https://doi.org/10.1016/S2666-5247(22)00390-1 Summary Background The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness and death is uncertain due to th...

COMMENT|ONLINE FIRST SARS-CoV-2 rebound with and without antivirals Nicola Petrosillo Lancet Infect Dis Published: February 13, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00063-4 As the COVID-19 pandemic continues, interventions for preventing SARS-CoV-2 transmission and progression to severe disease remain priorities. Vaccines against COVID-19 have an important role in preventing symptomatic infections that would otherwise lead to hospitalisation and d...

ARTICLES| VOLUME 4, ISSUE 3, E179-E191, MARCH 2023 Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis Bradley J Langford, Miranda So, Marina Simeonova, et al Lancet Microbe Published:January 31, 2023 DOI:https://doi.org/10.1016/S2666-5247(22)00355-X Summary Background Frequent use of antibiotics in patients with COVID-19 threatens to exacerbate antimicrobial resistance. We aimed to establish the pr...

World Sepsis Day The Global Sepsis Alliance (GSA) and the Sepsis Stiftung joined together to celebrate 10 years of World Sepsis Day on 16 September 2022 in Berlin, under the theme of " Making Sepsis a National and Global Health Priority”. The event aimed to engage with high-level policy makers, representatives of health authorities, patient organizations, health care providers, science, industry, and civil society, to learn from each other through networking a...

ARTICLES| VOLUME 4, ISSUE 3, E159-E170, MARCH 2023 Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study Jinnethe Reyes, Lauren Komarow, Liang Chen, et al. Lancet Microbe 2023; 4: E159-E170 Published: February 09, 2023 DOI:https://doi.org/10.1016/S2666-5247(22)00329-9 Summary Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a gl...

ARTICLES|ONLINE FIRST Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study Neil R Aggarwal, Kyle C Molina, Laurel E Beaty, et al. Lancet Infect Dis Published: February 10, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00011-7 Summary Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2, and ri...